Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	7/25/2005 2:02:02 PM
	of 3044

Millennium Pharmaceuticals "neutral," estimates raised Monday, July 25, 2005 10:26:25 AM ET Robert W. Baird NEW YORK, July 25 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on Millennium Pharmaceuticals (MLNM.NAS), while raising their estimates for the company. The target price is set to $10. In a research note published this morning, the analysts mention that the company has transferred its commercial responsibilities for the Integrilin product to its partner, Schering-Plough. Millennium Pharmaceuticals would receive an up-front payment of $35.5 million and $45-$50 million for existing inventories, in addition to royalty payments at a minimum of $85 million for 2006 and 2007, the analysts say. The deal is likely to be earnings neutral going forward, Robert W Baird adds. The EPS estimates for 2007 and 2008 have been reduced from $0.35 to $0.33 and from $0.49 to $0.47, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next